FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2109-2122 November 22, 2007 Number 21 Next

Abstract PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Rader, D. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib.

Methods We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina.

Results At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change.

Conclusions Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov] .)

Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from HDL to other lipoproteins; the inhibition of this protein raises HDL cholesterol levels and decreases low-density lipoprotein (LDL) cholesterol levels. There is evidence supporting CETP inhibition as a therapeutic approach to the prevention of major cardiovascular events, although there is also evidence to the contrary.^5,6,7

Torcetrapib is an inhibitor of CETP that has been shown to inhibit the development of atherosclerosis in rabbits.⁸ In early-phase studies in humans, the drug increased HDL cholesterol by 60 to 100% at the same time that it lowered LDL cholesterol by up to 20%.^9,10 Torcetrapib was subsequently investigated in three large trials with the use of ultrasonography and other imaging techniques and was found to have no significant effect on coronary atheroma burden¹¹ or carotid intima–media thickness.^12,13 Concurrent with these imaging studies, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial tested the proposition that torcetrapib would decrease the risk of clinical cardiovascular events. This trial was terminated prematurely on December 2, 2006, in a decision made by the sponsor on the basis of the recommendation of the trial's independent steering committee, which was acting on advice from the independent data and safety monitoring board.¹⁴ This report describes the main results of the ILLUMINATE trial.

Methods

Study Design

We conducted a prospective, randomized, multicenter, double-blind clinical trial, using a centralized randomization strategy with a block size of four. The trial was designed by an independent steering committee in collaboration with the sponsor, Pfizer. Data were collected by PharmaNet Development Group and analyzed independently by the Statistical Data Analysis Center at the University of Wisconsin, Madison; representatives of these organizations vouch for the completeness and veracity of the data and the analyses, respectively. An institutional review board at each center approved the protocol, and patients provided written informed consent. The original protocol was amended on November 28, 2006, a change that had not yet received institutional review board approval at the time of the trial's termination. The amendment included the addition of hospitalization for unstable angina to the primary outcome to increase the number of events and thus increase the statistical power to reject the null hypothesis.

Men and women between the ages of 45 and 75 years were eligible to participate in the study if they had a history of cardiovascular disease (including myocardial infarction, stroke, acute coronary syndrome, unstable angina, peripheral vascular disease, and cardiac revascularization) 30 days to 5 years before screening. Patients with type 2 diabetes without previous cardiovascular disease who met American Diabetes Association criteria or were receiving hypoglycemic agents were also eligible. Patients were excluded if they had evidence of an unstable medical condition, a life expectancy of less than 5 years, or an LDL cholesterol level of less than 100 mg per deciliter (2.6 mmol per liter) if the patient was not receiving a lipid-altering drug. Patients were also excluded if they had had a cardiovascular event during the run-in period or uncontrolled hypertension (defined as a systolic blood pressure of >140 mm Hg or a diastolic blood pressure of >90 mm Hg) or if the LDL cholesterol target level had not been reached at the end of the run-in period.

During a run-in period of 4 to 10 weeks, patients underwent lifestyle counseling and also received atorvastatin titrated (if needed) at 2-week intervals to achieve an LDL cholesterol level of less than 100 mg per deciliter. A variability tolerance of +15 mg per deciliter (0.4 mmol per liter) was allowed. Patients whose LDL level met the target were randomly assigned to receive either atorvastatin (at a dose established during the run-in period) plus 60 mg of torcetrapib or atorvastatin plus placebo. After termination of the trial, the sponsor maintained support for independent oversight during the trial's closeout (which involved four of the academic authors) with continuing support from the Statistical Data Analysis Center, which performed the primary statistical analyses.

Study Outcomes

Patients' visits were scheduled at 1, 3, 6, 9, and 12 months after randomization. Thereafter, patients were to be seen twice yearly. An increase or decrease in the dose of atorvastatin was allowed at the 12-month visit on the basis of predefined LDL cholesterol levels. The level of HDL cholesterol was determined through enzyme analysis with the use of polyethylene glycol–modified cholesterol esterase, cholesterol oxidase, and dextran sulfate to generate peroxide that was measured calorimetrically. Total cholesterol and triglyceride levels were determined by standard enzymatic techniques. LDL cholesterol was quantified by the Friedewald formula, except when the triglyceride level was more than 400 mg per deciliter (4.5 mmol per liter), in which case the level was measured by direct beta quantification. Apolipoproteins A-I and B-100 were measured by means of immunoturbidimetric assay. High-sensitivity C-reactive protein (CRP) was measured with the use of a particle-enhanced immunoturbidimetric assay. All measurements were performed at a central laboratory (MDS). Blood pressure was measured in triplicate at each visit with the use of a standard calibrated measuring device with the patient seated after 5 minutes of rest. The first reading was not used, and the latter two readings were averaged for the visit measurement. The estimated glomerular filtration rate was calculated as described previously.¹⁵

The QT interval was calculated with the use of Bazett's correction. A decision to measure aldosterone was made after termination of the trial after investigators observed a pattern of change in serum electrolytes and blood pressure. Stored serum samples that had been obtained from patients at baseline and at 3 months were used, with measurements made by means of liquid chromatography–tandem mass spectrometry (Mayo Central Laboratory for Clinic Trials).

Efficacy Measures

The primary outcome was the time to the first occurrence of a major cardiovascular event, a composite that included four components: death from coronary heart disease (defined as fatal myocardial infarction excluding procedure-related events, fatal heart failure, sudden cardiac death, or other cardiac death), nonfatal myocardial infarction (excluding procedure-related events), stroke, and hospitalization for unstable angina.

Secondary outcomes were the time to the first occurrence of each individual component of the primary outcome, the time to death from any cause, and the change from baseline in LDL and HDL cholesterol levels. Tertiary outcomes included further breakdowns in categories and composites of secondary outcomes.

Members of a central committee who were unaware of study-group assignments adjudicated potential outcomes as reported by the investigators. Adjudicated outcomes are not included in totals of adverse events and serious adverse events.

Statistical Analysis

The original design assumed a sample size of 13,000 patients (6500 per treatment group) to yield 551 primary outcomes in the atorvastatin-only group (8.48%) and 433 in the group receiving both atorvastatin and torcetrapib (6.66%) after an average of 4.5 years of follow-up — in other words, an absolute reduction of 1.82 percentage points or a relative reduction of 21% in the cumulative incidence. This number of patients would provide a statistical power of 90% to detect a treatment difference in the primary efficacy analysis at the two-sided level of 0.05 with the use of a log-rank test. A total of 15,067 patients underwent randomization, with overenrollment owing to an increase in screening activity after notification of an upcoming closure in enrollment at each site. On the basis of the modified primary outcome in the amended protocol and on the increased number of patients, the number of primary outcomes at an average follow-up of 4.5 years was expected to be 1820.

The prespecified safety-monitoring boundary (a P value <0.01, unadjusted for multiple comparisons) was based on a log-rank test for death from any cause. An efficacy-monitoring boundary (to be implemented after approximately 50% of the expected number of events had occurred in the primary outcome) was prespecified, but the requisite event count was never reached.

All treatment comparisons were performed with the use of an intention-to-treat analysis. All data were censored for the primary analyses on December 2, 2006, when the trial was terminated. Events occurring after that date, in the period between termination of the study and the end of data collection, are also reported. These events were captured either at a final visit after the discontinuation of a study drug (active surveillance) or as a result of instructions to patients to report serious adverse events (passive surveillance). The last adjudicated outcome reported during this observation period occurred on July 15, 2007.

P values for continuous and ordered categorical data were computed with the use of a nonparametric Wilcoxon test. Pearson's chi-square test (without continuity correction) was used for dichotomous and unordered categorical data. The log-rank test was used for time-to-event analyses. Post hoc exploratory analyses were also performed; only descriptive statistics were used to identify patterns of association, since these analyses were not inferential in nature. No adjustments have been made for multiple comparisons.

Results

Patients

Between August 23, 2004, and December 28, 2005, a total of 15,067 patients underwent randomization at 260 centers in seven countries. Of these patients, 7534 were assigned to receive atorvastatin plus placebo (atorvastatin-only group), and 7533 were assigned to receive torcetrapib plus atorvastatin (torcetrapib group) (Figure 1). At the end of the study on December 2, 2006, the median follow-up in each group was 550 days. Earlier discontinuation of treatment had occurred in 831 patients in the atorvastatin-only group (11.0%) and in 1008 patients in the torcetrapib group (13.4%). Higher rates of discontinuation owing to nonfatal adverse events in the torcetrapib group were associated mainly with a higher frequency of hypertension, nonspecific gastrointestinal symptoms, and headache. Follow-up was 99.7% complete, with 20 patients in the atorvastatin-only group and 19 patients in the torcetrapib group who were not followed until December 2, 2006. Baseline demographic and clinical characteristics of the two groups are presented in Table 1. Patients with a history of diabetes but no evidence of cardiovascular disease at study entry represented 18.8% of the atorvastatin-only group and 17.9% of the torcetrapib group (data not shown).

View larger version (27K): [in this window] [in a new window]   Figure 1. Enrollment and Outcomes. The numbers of deaths shown in the figure do not include those reported after the discontinuation of administration of a study drug on December 2, 2006.

 

View this table: [in this window] [in a new window]   Table 1. Demographic and Clinical Characteristics of the Patients.

 
Baseline and Follow-up Laboratory and Clinical Assessments

Changes in lipids were evident within the first month after randomization (Fig. 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). At 1 year, there were significant differences (P<0.001) between the torcetrapib group and the atorvastatin-only group. In the atorvastatin-only group, all lipid changes were minimal during the study; in the torcetrapib group, these changes included an increase of 72.1% in the HDL cholesterol, a decrease of 24.9% in LDL cholesterol, and a decrease of 9% in triglycerides (Table 2). Apolipoprotein measurements at 3 months reflected the changes in lipids. The mean increase in systolic blood pressure from baseline to month 12 was 5.4 mm Hg in the torcetrapib group, as compared with 0.9 mm Hg in the atorvastatin-only group (P<0.001). The change in high-sensitivity C-reactive protein from baseline to month 3 differed significantly between the two groups (P=0.01), but the magnitude of the difference (0.04 mg per liter) was small.

View this table: [in this window] [in a new window]   Table 2. Changes from Baseline at 3 Months and 12 Months in Selected Measures.

 
Electrolyte levels were similar in the two groups at baseline (Table 1). At 12 months, there was a mean decrease in potassium of 0.08 mmol per liter in the torcetrapib group, as compared with an increase of 0.06 mmol per liter in the atorvastatin-only group (P<0.001). After 12 months, 2.3% of patients in the torcetrapib group and 0.6% of patients in the atorvastatin-only group had potassium levels of less than 3.5 mmol per liter (P<0.001). In the torcetrapib group, as compared with the atorvastatin-only group, there were greater increases in levels of sodium (1.39 mmol per liter and 0.78 mmol per liter, respectively) and bicarbonate (2.28 mmol per liter and 1.93 mmol per liter, respectively; P<0.001).

At 12 months, the estimated glomerular filtration rate increased by 0.8 ml per minute per 1.73 m² of body-surface area in the torcetrapib group but decreased by 0.3 ml per minute per 1.73 m² in the atorvastatin-only group (P<0.001). The median change from baseline to month 12 in the QT interval was an increase of 3.3 msec in the torcetrapib group and a decrease of 0.3 msec in the atorvastatin-only group (P<0.001).

Post hoc measurements of aldosterone were performed for all patients for whom stored samples from both baseline and 3 months were available. One percent of samples submitted to the laboratory were of insufficient volume to permit analysis. Analysis was performed on baseline samples obtained from 6745 patients in the atorvastatin-only group (90.0%) and 6662 patients in the torcetrapib group (88.5%) and on samples obtained at 3 months for 6664 patients (88.4%) and 6562 patients (87.1%), respectively. Most analyzed samples (56.5% in the atorvastatin-only group and 52.7% in the torcetrapib group) had aldosterone levels below the lower limit of quantification for the test used (<4 ng per deciliter for samples with sufficient volume for undiluted testing and <8 ng per deciliter for samples with insufficient volume requiring dilution). Because of this, a direct comparison of median or mean values was not possible with these data. However, it was possible to calculate values in the 85th percentile and above, since this calculation depended only on the values of 8 ng per deciliter or more for which data were complete. At baseline, the 85th, 90th, and 95th percentiles were 8.5, 10.0, and 13.0 ng per deciliter, respectively, in the atorvastatin-only group and 8.3, 10.0, and 13.0 ng per deciliter, respectively, in the torcetrapib group (P=0.21). At 3 months, these percentiles were 8.6, 10.0, and 13.0 ng per deciliter in the atorvastatin-only group and 9.5, 11.0, and 14.0 ng per deciliter in the torcetrapib group (P<0.001). (The P values are Wilcoxon comparisons performed after truncating the data below 8 ng per deciliter.)

Study Outcomes

Figures 2A and 2B show Kaplan–Meier curves for death from any cause and the primary composite outcome. The hazard ratio for the primary outcome — major cardiovascular events — was 1.25 in the torcetrapib group, as compared with the atorvastatin-only group (95% confidence interval [CI], 1.09 to 1.44; P=0.001) (Table 3). The hazard ratio estimates for the individual components of the composite outcome ranged from 1.35 for hospitalization for unstable angina (P=0.001) to 1.08 for stroke (P=0.74).

View larger version (43K): [in this window] [in a new window]   Figure 2. Kaplan–Meier Curves for Death from Any Cause and for the Primary Composite Outcome. Panel A shows the between-group comparison of patients who died from any cause during the study: 59 patients in the atorvastatin-only group and 93 patients in the torcetrapib group. Panel B shows the between-group comparison of patients who had the primary composite outcome: 373 patients in the atorvastatin-only group and 464 patients in the torcetrapib group. The primary outcome was the time to the first occurrence of a major cardiovascular event, a composite that included four components: death from coronary heart disease, nonfatal myocardial infarction (excluding procedure-related events), stroke, and hospitalization for unstable angina. Analyses in both panels were censored on December 2, 2006.

 

View this table: [in this window] [in a new window]   Table 3. Estimated Hazard Ratios for Protocol-Specified Cardiovascular Outcomes.

 
At study termination, there were 93 deaths in the torcetrapib group and 59 in the atorvastatin-only group, for a hazard ratio of 1.58 in the torcetrapib group (95% CI, 1.14 to 2.19; P=0.006). The adjudicated causes of death are shown in Table 4. There was no significant interaction between study-group assignment and cause of death (P=0.18). In the torcetrapib group, as compared with the atorvastatin-only group, there was an increased risk of death from both cardiovascular causes (49 vs. 35) and noncardiovascular causes (40 vs. 20). No single cause of death explained the increased cardiovascular risks. For death from noncardiovascular causes, more patients in the torcetrapib group than in the atorvastatin-only group died from cancer (24 vs. 14) and infection (9 vs. 0). The primary sites of fatal cancers were similar in the two groups (Table 1 of the Supplementary Appendix). Seven of the nine deaths from infection were in patients with diabetes.

View this table: [in this window] [in a new window]   Table 4. Causes of Death.

 
Numbers of reported major cardiovascular events and deaths occurring after the termination of the trial were similar in the two groups: 38 major cardiovascular events in each group, with 14 deaths in the torcetrapib group and 20 deaths in the atorvastatin-only group.

Adverse Events

Adverse events were reported in 86.6% of patients in the torcetrapib group and in 83.3% of patients in the atorvastatin-only group (P<0.001). Among events that were significantly more frequent in the torcetrapib group than in the atorvastatin-only group were reported hypertension, which occurred in 1411 patients (18.7%) and 564 patients (7.5%, P<0.001), respectively; peripheral edema, in 467 (6.2%) and 353 (4.7%, P<0.001); angina pectoris, in 451 (6.0%) and 360 (4.8%, P=0.001); dyspnea, in 313 (4.2%) and 243 (3.2%, P=0.003); and headache, in 412 (5.5%) and 296 (3.9%, P<0.001). Serious adverse events were reported more frequently in the torcetrapib group than in the atorvastatin-only group (16.4% vs. 15.0%, P=0.02) (Table 2 of the Supplementary Appendix). Reported neoplasms (128 in the torcetrapib group and 136 in the atorvastatin-only group) and infections or infestations (182 and 177) were reported with similar frequencies in the two groups.

Post Hoc Exploratory Analyses

Post-randomization changes in selected measurements in the torcetrapib group were examined for their relationship to major cardiovascular events and death from any cause and from coronary heart disease (Table 5). The numbers and rates for these outcomes are given for subgroups whose change in the indicated measure from baseline to month 1 (or to month 3 for apolipoprotein A-I) was at or below the study-group median, as compared with above the median. The earliest time points were chosen to capture the maximum amount of information available before death. For death from any cause, higher rates were observed in association with greater decreases in potassium and greater increases in bicarbonate. For major cardiovascular events, lower rates were apparent in those with greater increases in HDL cholesterol and apolipoprotein A-I and for those who had smaller decreases in potassium and increases in bicarbonate. Paradoxically, there was an increased risk of death and major cardiovascular events in patients whose increase in systolic blood pressure was less than the median. It should be emphasized that the results shown in Table 5 were both exploratory and post hoc.

View this table: [in this window] [in a new window]   Table 5. Relationship between Changes from Baseline to 1 Month in Key Measurements and Death from Any Cause or from Coronary Heart Disease and the Primary Outcome among 7533 Patients Who Received Torcetrapib.

 
Discussion

The increased mortality associated with the use of torcetrapib included increased risks of death from both cardiovascular and noncardiovascular causes. There was also a significant increase in the risk of major cardiovascular events in the torcetrapib-treated group. The question arises: By what mechanism did torcetrapib cause harm?

Clinical trials such as ours are not designed to elucidate mechanisms of either benefit or harm associated with the use of a drug. However, they may provide clues that have the potential to inform future research. To this end, we conducted a series of exploratory post hoc analyses in an attempt to gain some insight into what might have occurred.

There are at least two possible explanations for the observation of increased mortality and morbidity associated with the use of torcetrapib in our study: an off-target effect of torcetrapib, unrelated to CETP inhibition, and an adverse effect of CETP inhibition per se, with the possible generation of dysfunctional or even proatherogenic HDL cholesterol.

A known off-target effect of torcetrapib is an increase in blood pressure. At 12 months in our study, systolic blood pressure increased by a mean of 5.4 mm Hg in the torcetrapib group from baseline, a greater effect than had been observed in earlier studies of shorter duration^9,10 but consistent with the longer phase 3 imaging trials.^11,13 The relationship between changes in blood pressure and clinical outcome in the torcetrapib group was counterintuitive, with an apparent increased risk of death in patients whose increase in systolic blood pressure was less than the median. However, it appeared that an increase in blood pressure above the median identified a group with lower baseline blood pressure levels, making it difficult to interpret the relationship without further analysis. The observed reduction in potassium and increases in sodium and bicarbonate in the torcetrapib group, as compared with the atorvastatin-only group, raised the possibility that the increase in blood pressure may have been a manifestation of mineralocorticoid excess. This proposition gained further support from post hoc findings of an increase in aldosterone levels in the torcetrapib group. The mechanism by which torcetrapib may have increased aldosterone levels is unknown.

Although cardiovascular events caused by a torcetrapib-induced increase in aldosterone is one possible explanation for the observed adverse outcomes, it does not rule out other unknown off-target effects of the agent. Nor does it rule out the possibility that CETP inhibition per se may have adverse effects. It has been suggested that the inhibition of CETP may generate HDL particles that are nonfunctional or even proatherogenic.¹⁶ Our study does not address the issue of how torcetrapib has a functional effect on HDL particles, although it was interesting to note that in the torcetrapib group, rates of cardiovascular events and death from coronary heart disease were lower in those whose increase in HDL cholesterol or apolipoprotein A-I was greater than the median. However, it must be emphasized that these post hoc observations are merely suggestive and do not rule out HDL dysfunctionality, nor do they rule out the possibility that other unknown effects of CETP inhibition may have contributed to a mechanism-related adverse outcome.

In conclusion, our study neither validates nor invalidates the hypothesis that raising levels of HDL cholesterol by the inhibition of CETP may be cardioprotective. Thus, the possibility that the inhibition of CETP may be beneficial will remain hypothetical until it is put to the test in a trial with a CETP inhibitor that does not share the off-target pharmacologic effects of torcetrapib.

Supported by Pfizer.

Dr. Barter reports receiving consulting fees from Abbott, AstraZeneca, CSL, Genfit, LifeCycle Pharma, Merck, Pfizer, and Resverlogix, lecture fees from Abbott, AstraZeneca, Merck, Pfizer, and Sanofi–Aventis, and grant support from Pfizer; Dr. Caulfield, consulting fees from Novartis and Pfizer, lecture fees from Novartis, Servier, and Pfizer, and grant support from Pfizer and Novartis; Dr. Eriksson, consulting fees from AstraZeneca, Abbott, Sanofi–Aventis, and Pfizer, lecture fees from Merck Sharp & Dohme, and grant support from AstraZeneca and Merck–Schering-Plough, and having equity interests in KaroBio and Biophausia; Dr. Grundy, consulting fees from Merck, Merck–Schering-Plough, AstraZeneca, and Pfizer, and grant support from Merck and Abbott; Dr. Kastelein, consulting fees from Pfizer, AstraZeneca, Merck, and Merck–Schering-Plough, lecture fees from Pfizer, AstraZeneca, and Merck–Schering-Plough, and grant support from Pfizer and AstraZeneca; Dr. Komajda, consulting fees from Pfizer and Servier and lecture fees from AstraZeneca, Sanofi Synthelabo, and Bristol-Myers Squibb; Dr. Lopez-Sendon, consulting fees from Pfizer, Servier, CV Therapeutics, and Lilly, lecture fees from Pfizer, Servier, and Lilly, and grant support from Pfizer, Servier, Lilly, Bristol-Myers Squibb, and Bayer; Dr. Mosca, consulting fees and grant support from Pfizer; Dr. Tardif, consulting fees and grant support from Pfizer and lecture fees from Pfizer and AstraZeneca; Dr. Waters, consulting fees from Pfizer and Merck–Schering-Plough and lecture fees from Pfizer; Drs. Shear and Revkin, being employees of Pfizer and holding equity or other ownership interest in the company; Dr. Fisher, consulting fees from Boehringer Ingelheim, Genentech, GlaxoSmithKline, and Novartis and grant support from Pfizer, GlaxoSmithKline, and Novartis; Dr. Buhr, grant support from Pfizer; Dr. Tall, consulting fees from AstraZeneca, Pfizer, Merck and Roche, lecture fees from Merck, and grant support from Merck and Pfizer; and Dr. Brewer, consulting and lecture fees from Pfizer, Merck, and Roche. No other conflict of interest relevant to this article was reported.

We thank Pfizer representatives Diane T. Hessinger, William C. Ports, Lynne M. Dugan, Allison G. O'Reilly, William T. Duggan, Robert Burnside, Darlene Ambrose, and Andrea J. Maynard for their efforts in the conduct of this study; and Thomas D. Cook and Michelle A. Detry of the Department of Biostatistics and Medical Informatics at the University of Wisconsin, Madison.

^* Members of the committees of the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial are listed in the Appendix. All investigators are listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org.

Source Information

From the Heart Research Institute, Sydney (P.J.B.); St. Bartholomew's Hospital, London (M.C.); Karolinska University Hospital, Huddinge, Stockholm (M.E.); University of Texas Southwestern Medical Center, Dallas (S.M.G.); Academic Medical Center, University of Amsterdam, Amsterdam (J.J.P.K.); University Pierre et Marie Curie and Hôpital Pitié–Salpêtrière, Paris (M.K.); Hospital Universitario La Paz, Madrid (J.L.-S.); Columbia University, New York (L.M.); Montreal Heart Institute, Montreal (J.-C.T.); San Francisco General Hospital, San Francisco (D.D.W.); Pfizer, New London, CT (C.L.S., J.H.R.); University of Wisconsin, Madison (K.A.B., M.R.F.); Columbia University Medical Center, New York (A.R.T.); and Medstar Institute, Washington, DC (B.B.).

This article (10.1056/NEJMoa0706628) was published at www.nejm.org on November 5, 2007.

Address reprint requests to Dr. Barter at the Heart Research Institute, 145 Missenden Rd., Camperdown, Sydney, NSW 2050, Australia, or at barterp{at}hri.org.au.

References

1. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discovery 2005;4:193-205. 
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15. [Free Full Text]
3. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006;111:893-908. [CrossRef][Web of Science][Medline]
4. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310. [Free Full Text]
5. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 2000;11:589-596. [CrossRef][Web of Science][Medline]
6. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167. [Free Full Text]
7. Barter PJ, Kastelein JP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47:492-499. [Free Full Text]
8. Morehouse LA, Sugarman ED, Bourassa P-A, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in NZW rabbits. J Lipid Res 2007;48:1263-1272. [Free Full Text]
9. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-1515. [Free Full Text]
10. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006;48:1782-1790. [Free Full Text]
11. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-1316. [Erratum, N Engl J Med 2007;357:835.] [Free Full Text]
12. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-1630. [Free Full Text]
13. Bots ML, Visseren FLJ, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-160. [CrossRef][Web of Science][Medline]
14. In interests of patient safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer news release, December 2, 2006. (Accessed October 30, 2007, at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01514.html.)
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470. [Free Full Text]
16. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-798. [Erratum, JAMA 2007;298:1516.] [Free Full Text]

Committee members of the ILLUMINATE trial are as follows: Steering Committee — P.J. Barter, Heart Research Institute, Sydney (chair); M. Caulfield, the Royal London School of Medicine, London; M. Eriksson, Karolinska University Hospital, Huddinge, Stockholm; S. Grundy, University of Texas Southwestern Medical Center, Dallas; J. Kastelein, Academic Medical Center, Amsterdam; M. Komajda, University Pierre et Marie Curie, Paris; J. Lopez-Sendon, Hospital Universitario La Paz, Madrid; L. Mosca, Columbia University, New York; J.-C. Tardif, Montreal Heart Institute, Montreal; D. Waters, San Francisco General Hospital, San Francisco. Clinical Outcome Adjudication Committee — B. O'Neil, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (chair); C. O'Connor, Duke University Medical Center, Durham, NC; U. Sechtem, Robert Bosch Krankenhaus, Stuttgart, Germany; J.-M. LaBlanche, Hôpital Cardiologique, Lille, France; F. Welty, Beth Israel Deaconess Medical Center, Boston; J.D. Easton, Brown University, Providence, RI; M.M. Brown, University College, London; I.E. Silverman, the Stroke Center at Hartford Hospital, Hartford, CT.

Abstract PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Rader, D. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Related Letters:

Torcetrapib and Coronary Events
Lackner K. J., Cohn L. J., Dullaart R. P., Kobold A. C. M., van Tol A., Barter P., Shear C. L., Revkin J. H., Rader D. J.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1862-1864, Apr 24, 2008. Correspondence

This article has been cited by other articles:

• Smith, J. D. (2010). Dysfunctional HDL as a Diagnostic and Therapeutic Target. Arterioscler. Thromb. Vasc. Bio. 30: 151-155 [Abstract] [Full Text]  
• Funder, J. W. (2010). Aldosterone, Sodium, and Hypertension: Lessons From Torcetrapib?. Hypertension 55: 221-223 [Full Text]  
• Ritsch, A., Scharnagl, H., Eller, P., Tancevski, I., Duwensee, K., Demetz, E., Sandhofer, A., Boehm, B. O., Winkelmann, B. R., Patsch, J. R., Marz, W. (2010). Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 121: 366-374 [Abstract] [Full Text]  
• van Schalkwijk, D. B., van Bochove, K., van Ommen, B., Freidig, A. P., van Someren, E. P., van der Greef, J., de Graaf, A. A. (2010). Developing computational model-based diagnostics to analyse clinical chemistry data. Brief Bioinform 0: bbp071v1-bbp071 [Abstract] [Full Text]  
• Sofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T., Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., Wareham, N., Khaw, K. T., Kumari, M., Kivimaki, M., Marmot, M., Asselbergs, F. W., van der Harst, P., Dullaart, R. P.F., Navis, G., van Veldhuisen, D. J., Van Gilst, W. H., Thompson, J. F., McCaskie, P., Palmer, L. J., Arca, M., Quagliarini, F., Gaudio, C., Cambien, F., Nicaud, V., Poirer, O., Gudnason, V., Isaacs, A., Witteman, J. C.M., van Duijn, C. M., Pencina, M., Vasan, R. S., D'Agostino, R. B. Sr, Ordovas, J., Li, T. Y., Kakko, S., Kauma, H., Savolainen, M. J., Kesaniemi, Y. A., Sandhofer, A., Paulweber, B., Sorli, J. V., Goto, A., Yokoyama, S., Okumura, K., Horne, B. D., Packard, C., Freeman, D., Ford, I., Sattar, N., McCormack, V., Lawlor, D. A., Ebrahim, S., Smith, G. D., Kastelein, J. J.P., Deanfield, J., Casas, J. P. (2010). Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. Circulation 121: 52-62 [Abstract] [Full Text]  
• Sorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horvath, T., Doerries, C., Heinemann, M., Flemmer, S., Markowski, A., Manes, C., Bahr, M. J., Haller, H., von Eckardstein, A., Drexler, H., Landmesser, U. (2010). Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy. Circulation 121: 110-122 [Abstract] [Full Text]  
• Chapman, M. J., Le Goff, W., Guerin, M., Kontush, A. (2010). Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31: 149-164 [Abstract] [Full Text]  
• Bijland, S., van den Berg, S. A. A., Voshol, P. J., van den Hoek, A. M., Princen, H. M. G., Havekes, L. M., Rensen, P. C. N., Willems van Dijk, K. (2010). CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice. J. Lipid Res. 51: 97-102 [Abstract] [Full Text]  
• Wu, Z., Gogonea, V., Lee, X., Wagner, M. A., Li, X.-M., Huang, Y., Undurti, A., May, R. P., Haertlein, M., Moulin, M., Gutsche, I., Zaccai, G., DiDonato, J. A., Hazen, S. L. (2009). Double Superhelix Model of High Density Lipoprotein. J. Biol. Chem. 284: 36605-36619 [Abstract] [Full Text]  
• Vasan, R. S., Pencina, M. J., Robins, S. J., Zachariah, J. P., Kaur, G., D'Agostino, R. B., Ordovas, J. M. (2009). Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community. Circulation 120: 2414-2420 [Abstract] [Full Text]  
• Shah, P. K. (2009). The Yin and Yang of Cholesteryl Ester Transfer Protein in Cardiovascular Disease. Circulation 120: 2408-2410 [Full Text]  
• Cheung, A. K. (2009). Is Lipid Control Necessary in Hemodialysis Patients?. CJASN 4: S95-S101 [Abstract] [Full Text]  
• Blumenthal, R. S., Michos, E. D. (2009). The HALTS Trial -- Halting Atherosclerosis or Halted Too Early?. NEJM 361: 2178-2180 [Full Text]  
• The Emerging Risk Factors Collaboration, (2009). Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA 302: 1993-2000 [Abstract] [Full Text]  
• Lee, J. M.S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., Durrington, P. N., Channon, K. M., Neubauer, S., Choudhury, R. P. (2009). Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study.. J Am Coll Cardiol 54: 1787-1794 [Abstract] [Full Text]  
• Ong, H. T. (2009). Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?. J Am Board Fam Med 22: 686-697 [Abstract] [Full Text]  
• Potter, L. K., Sprecher, D. L., Walker, M. C., Tobin, F. L. (2009). Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro. J. Lipid Res. 50: 2222-2234 [Abstract] [Full Text]  
• Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., Harats, D. (2009). Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?. Diabetes Care 32: S373-S377 [Full Text]  
• Grover, S. A., Kaouache, M., Joseph, L., Barter, P., Davignon, J. (2009). Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels. Arch Intern Med 169: 1775-1780 [Abstract] [Full Text]  
• Whayne, T. F. Jr (2009). High-density Lipoprotein Cholesterol: Current Perspective for Clinicians. ANGIOLOGY 60: 644-649 [Abstract]  
• Bloomgarden, Z. T. (2009). The 6th Annual World Congress on the Insulin Resistance Syndrome. Diabetes Care 32: e114-e121 [Full Text]  
• Swedberg, K. (2009). Fallacies in clinical cardiovascular trials. Heart 95: 1464-1468 [Full Text]  
• Franssen, R., Sankatsing, R. R., Hassink, E., Hutten, B., Ackermans, M. T., Brinkman, K., Oesterholt, R., Arenas-Pinto, A., Storfer, S. P., Kastelein, J. J., Sauerwein, H. P., Reiss, P., Stroes, E. S. (2009). Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production. Arterioscler. Thromb. Vasc. Bio. 29: 1336-1341 [Abstract] [Full Text]  
• Rader, D. J. (2009). Lecithin: Cholesterol Acyltransferase and Atherosclerosis: Another High-Density Lipoprotein Story That Doesn't Quite Follow the Script. Circulation 120: 549-552 [Full Text]  
• Krumholz, H. M. (2009). Medicine Should Be More Like Missouri. Circ Cardiovasc Qual Outcomes 2: 289-291 [Full Text]  
• Brousseau, M. E., Millar, J. S., Diffenderfer, M. R., Nartsupha, C., Asztalos, B. F., Wolfe, M. L., Mancuso, J. P., Digenio, A. G., Rader, D. J., Schaefer, E. J. (2009). Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. J. Lipid Res. 50: 1456-1462 [Abstract] [Full Text]  
• Funder, J. W. (2009). The Off-Target Effects of Torcetrapib. Endocrinology 150: 2024-2026 [Full Text]  
• Hu, X., Dietz, J. D., Xia, C., Knight, D. R., Loging, W. T., Smith, A. H., Yuan, H., Perry, D. A., Keiser, J. (2009). Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition. Endocrinology 150: 2211-2219 [Abstract] [Full Text]  
• Drew, B. G., Duffy, S. J., Formosa, M. F., Natoli, A. K., Henstridge, D. C., Penfold, S. A., Thomas, W. G., Mukhamedova, N., de Courten, B., Forbes, J. M., Yap, F. Y., Kaye, D. M., van Hall, G., Febbraio, M. A., Kemp, B. E., Sviridov, D., Steinberg, G. R., Kingwell, B. A. (2009). High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus. Circulation 119: 2103-2111 [Abstract] [Full Text]  
• Fazio, S., Linton, M. F. (2009). Elevated High-Density Lipoprotein (HDL) Levels due to Hepatic Lipase Mutations Do Not Reduce Cardiovascular Disease Risk: Another Strike against the HDL Dogma. J. Clin. Endocrinol. Metab. 94: 1081-1083 [Full Text]  
• Masson, D., Jiang, X.-C., Lagrost, L., Tall, A. R. (2009). The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J. Lipid Res. 50: S201-S206 [Abstract] [Full Text]  
• Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., Barter, P. J. (2009). The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50: S195-S200 [Abstract] [Full Text]  
• Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J., Rothblat, G. H. (2009). The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50: S189-S194 [Abstract] [Full Text]  
• Wenzel, P., Munzel, T. (2009). From Menace to Marvel: High-Density Lipoprotein Prevents Endothelial Nitric Oxide Synthase Uncoupling in Diabetes Mellitus by Angiotensin II Type 1 Receptor Downregulation. Hypertension 53: 587-589 [Full Text]  
• Plump, A. S., Lum, P. Y. (2009). Genomics and cardiovascular drug development.. J Am Coll Cardiol 53: 1089-1100 [Abstract] [Full Text]  
• Meuwese, M. C., de Groot, E., Duivenvoorden, R., Trip, M. D., Ose, L., Maritz, F. J., Basart, D. C. G., Kastelein, J. J. P., Habib, R., Davidson, M. H., Zwinderman, A. H., Schwocho, L. R., Stein, E. A., for the CAPTIVATE Investigators, (2009). ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia: The CAPTIVATE Randomized Trial. JAMA 301: 1131-1139 [Abstract] [Full Text]  
• Krumholz, H. M. (2009). Questioning Conventional Wisdom. Circ Cardiovasc Qual Outcomes 2: 59-60 [Full Text]  
• Mak, A., Ho, R. C.-M., Tan, J. Y.-S., Teng, G. G., Lahiri, M., Lateef, A., Vasoo, S., Boey, M. L., Koh, D. R., Feng, P. H. (2009). Atherogenic serum lipid profile is an independent predictor for gouty flares in patients with gouty arthropathy. Rheumatology (Oxford) 48: 262-265 [Abstract] [Full Text]  
• Ross, J. S., Gross, C. P. (2009). Policy Research: Using Evidence to Improve Healthcare Delivery Systems. Circulation 119: 891-898 [Full Text]  
• Briel, M., Ferreira-Gonzalez, I., You, J. J, Karanicolas, P. J, Akl, E. A, Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., Whitt, I., Alves da Silva, S., Khalid, Z., Nordmann, A. J, Zhou, Q., Walter, S. D, Vale, N., Bhatnagar, N., O'Regan, C., Mills, E. J, Bucher, H. C, Montori, V. M, Guyatt, G. H (2009). Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338: b92-b92 [Abstract] [Full Text]  
• Ridker, P. M., Pare, G., Parker, A. N., Zee, R. Y.L., Miletich, J. P., Chasman, D. I. (2009). Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women From the Women's Genome Health Study. Circ Cardiovasc Genet 2: 26-33 [Abstract] [Full Text]  
• El Harchaoui, K., Arsenault, B. J., Franssen, R., Despres, J.-P., Hovingh, G. K., Stroes, E. S.G., Otvos, J. D., Wareham, N. J., Kastelein, J. J.P., Khaw, K.-T., Boekholdt, S. M. (2009). High-Density Lipoprotein Particle Size and Concentration and Coronary Risk. ANN INTERN MED 150: 84-93 [Abstract] [Full Text]  
• Mackness, B., Mackness, M. (2009). High-density lipoprotein: why all the fuss?. Ann Clin Biochem 46: 5-7 [Abstract] [Full Text]  
• Fleg, J. L., Mete, M., Howard, B. V., Umans, J. G., Roman, M. J., Ratner, R. E., Silverman, A., Galloway, J. M., Henderson, J. A., Weir, M. R., Wilson, C., Stylianou, M., Howard, Wm. J. (2008). Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial. J Am Coll Cardiol 52: 2198-2205 [Abstract] [Full Text]  
• Pfeffer, M. A., Sacks, F. M. (2008). Leapfrogging Data: No Shortcuts for Safety or Efficacy Information. Circulation 118: 2491-2494 [Full Text]  
• Vergeer, M., Bots, M. L., van Leuven, S. I., Basart, D. C., Sijbrands, E. J., Evans, G. W., Grobbee, D. E., Visseren, F. L., Stalenhoef, A. F., Stroes, E. S., Kastelein, J. J.P. (2008). Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials. Circulation 118: 2515-2522 [Abstract] [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J.-C., Nissen, S. E. (2008). Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506-2514 [Abstract] [Full Text]  
• Roberts, C. K., Barnard, R. J., Croymans, D. M., Astrup, A., Moller, K., Krogh-Madsen, R., Ornish, D., Manzoni, G. M., Castelnuovo, G., Molinari, E., Shai, I., Henkin, Y., Stampfer, M. J. (2008). Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet. NEJM 359: 2169-2172 [Full Text]  
• Freiberg, J. J., Tybjaerg-Hansen, A., Jensen, J. S., Nordestgaard, B. G. (2008). Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population. JAMA 300: 2142-2152 [Abstract] [Full Text]  
• Lange, R. A., Lindsey, M. L. (2008). HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Eur Heart J 29: 2708-2709 [Full Text]  
• Regieli, J. J., Jukema, J. W., Grobbee, D. E., Kastelein, J. J.P., Kuivenhoven, J. A., Zwinderman, A. H., van der Graaf, Y., Bots, M. L., Doevendans, P. A. (2008). CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 29: 2792-2799 [Abstract] [Full Text]  
• Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P. (2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research 5: 319-335 [Abstract]  
• DAVIDSON, M. H. (2008). IN REPLY. Cleveland Clinic Journal of Medicine 75: 767-767 [Full Text]  
• Legro, R. S. (2008). Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women: Do We Need a New Drug?. J. Clin. Endocrinol. Metab. 93: 4218-4220 [Full Text]  
• Seiler, S., Schlitt, A., Jiang, X.-C., Ulrich, C., Blankenberg, S., Lackner, K. J., Girndt, M., Werdan, K., Buerke, M., Fliser, D., Heine, G. H. (2008). Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrol Dial Transplant 23: 3599-3604 [Abstract] [Full Text]  
• Watts, G.F., Chan, D.C. (2008). Of Mice and Men: Blowing Away the Cobwebs From the Mechanism of Action of Niacin on HDL Metabolism. Arterioscler. Thromb. Vasc. Bio. 28: 1892-1895 [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad. Med. J. 84: 590-598 [Abstract] [Full Text]  
• Roe, M. T., Ou, F.-S., Alexander, K. P., Newby, L. K., Foody, J. M., Gibler, W. B., Boden, W. E., Ohman, E. M., Smith, S. C. Jr, Peterson, E. D. (2008). Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 29: 2480-2488 [Abstract] [Full Text]  
• Lo, B., Kriegstein, A., Grady, D. (2008). Clinical trials in stem cell transplantation: guidelines for scientific and ethical review. Clin Trials 5: 517-522 [Abstract]  
• Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J., Moore, A. B., Marcovina, S., Brunzell, J., Knopp, R. H., Zhao, X.-Q., Heinecke, J. W. (2008). Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome. Circulation 118: 1259-1267 [Abstract] [Full Text]  
• Davidson, M. H. (2008). Is LDL-C Passed Its Prime?: The Emerging Role of Non-HDL, LDL-P, and ApoB in CHD Risk Assessment. Arterioscler. Thromb. Vasc. Bio. 28: 1582-1583 [Full Text]  
• Lunde, K., Aakhus, S. (2008). Cell therapy in acute myocardial infarction: measures of efficacy. Heart 94: 969-970 [Full Text]  
• Su, Y. R., Blakemore, J. L., Zhang, Y., Linton, M. F., Fazio, S. (2008). Lentiviral Transduction of ApoAI Into Hematopoietic Progenitor Cells and Macrophages: Applications to Cell Therapy of Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 28: 1439-1446 [Abstract] [Full Text]  
• Laaksonen, R., Janis, M. T., Oresic, M. (2008). Lipidomics-Based Safety Biomarkers for Lipid-Lowering Treatments. ANGIOLOGY 59: 65S-68S [Abstract]  
• Andrikopoulos, G. K., Tzeis, S. (2008). Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism. ANGIOLOGY 59: 44S-48S [Abstract]  
• Mintz, G. S. (2008). Diabetic Coronary Artery Disease: How Little We Know and How Little Intravascular Ultrasound Has Taught Us. J Am Coll Cardiol 52: 263-265 [Full Text]  
• DAVIDSON, M. H. (2008). Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic Journal of Medicine 75: 479-496 [Full Text]  
• Thompson, A., Di Angelantonio, E., Sarwar, N., Erqou, S., Saleheen, D., Dullaart, R. P. F., Keavney, B., Ye, Z., Danesh, J. (2008). Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk. JAMA 299: 2777-2788 [Abstract] [Full Text]  
• deGoma, E. M., deGoma, R. L., Rader, D. J. (2008). Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.. J Am Coll Cardiol 51: 2199-2211 [Abstract] [Full Text]  
• Frikke-Schmidt, R., Nordestgaard, B. G., Stene, M. C. A., Sethi, A. A., Remaley, A. T., Schnohr, P., Grande, P., Tybjaerg-Hansen, A. (2008). Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease. JAMA 299: 2524-2532 [Abstract] [Full Text]  
• Zhang, L.-H., Kamanna, V. S., Zhang, M. C., Kashyap, M. L. (2008). Niacin inhibits surface expression of ATP synthase {beta} chain in HepG2 cells: implications for raising HDL. J. Lipid Res. 49: 1195-1201 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Cardiovascular Disease in Diabetes. Diabetes Care 31: 1260-1266 [Full Text]  
• Wild, S., Byrne, C. D (2008). Time to rethink high-density lipoprotein?. Heart 94: 692-694 [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94: 706-714 [Abstract] [Full Text]  
• Ballantyne, C. M., Raichlen, J. S., Nicholls, S. J., Erbel, R., Tardif, J.-C., Brener, S. J., Cain, V. A., Nissen, S. E., for the ASTEROID Investigators, (2008). Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden. Circulation 117: 2458-2466 [Abstract] [Full Text]  
• de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W.A., Gautier, T., van der Hoogt, C. C., Westerterp, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M.G., Rensen, P. C.N. (2008). Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation 117: 2515-2522 [Abstract] [Full Text]  
• Movva, R., Rader, D. J. (2008). Laboratory Assessment of HDL Heterogeneity and Function. Clin. Chem. 54: 788-800 [Abstract] [Full Text]  
• Lackner, K. J., Cohn, L. J., Dullaart, R. P., Kobold, A. C. M., van Tol, A., Barter, P., Shear, C. L., Revkin, J. H., Rader, D. J. (2008). Torcetrapib and Coronary Events. NEJM 358: 1862-1864 [Full Text]  
• Davidson, M., Meyer, P. M., Haffner, S., Feinstein, S., D'Agostino, R. Sr, Kondos, G. T., Perez, A., Chen, Z., Mazzone, T. (2008). Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus. Circulation 117: 2123-2130 [Abstract] [Full Text]  
• Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512-1524 [Full Text]  
• Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31: 811-822 [Full Text]  
• Psaty, B. M., Lumley, T. (2008). Surrogate End Points and FDA Approval: A Tale of 2 Lipid-Altering Drugs. JAMA 299: 1474-1476 [Full Text]  
• Sanz, J., Moreno, P. R., Fuster, V. (2008). The year in atherothrombosis.. J Am Coll Cardiol 51: 944-955 [Full Text]  
• Levy, Y. (2008). High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovasc Res 77: 614-615 [Full Text]  
• Malgarini, R. B., Pimpinella, G., Falutz, J., Grinspoon, S. (2008). Zoledronate, fractures, and mortality after hip fracture.. NEJM 358: 969-969 [Full Text]